TORONTO, May 25, 2017/CNW/ - Fahar Merchant, PhD, Co-Founder, Chairman, President and CEO, Medicenna Therapeutics Corp. (MDNA), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market. Medicenna is a clinical stage immuno-oncology company that is developing therapeutics for the treatment of central nervous system cancers. Medicenna Therapeutics Corp. commenced trading on the TSX Venture Exchange on March 3, 2017.
SOURCE TMX Group Limited
View original content with multimedia: http://www.newswire.ca/en/releases/archive/May2017/25/c3076.html
